deltatrials
Completed NA INTERVENTIONAL 1-arm NCT00643994

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution

Sponsor: Accuray Incorporated

Updated 12 times since 2017 Last updated: Apr 17, 2023 Started: Dec 31, 2007 Primary completion: Jan 27, 2021 Completion: Jan 27, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00643994, this NA trial focuses on Cancer of the Prostate and Prostate Cancer and remains completed. Sponsored by Accuray Incorporated, it has been updated 12 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.

The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotActive Not Recruiting~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshotUnknown Status~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotActive Not Recruiting~Apr 2021 – ~Feb 2023 · 22 months · monthly snapshotActive Not Recruiting~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshotUnknown Status~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Sep 2024 — Sep 2025 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Jun 2023 — Jul 2024 [monthly]

    Completed NA

    Status: Unknown StatusCompleted

  5. Feb 2023 — Jun 2023 [monthly]

    Unknown Status NA

    Status: Active Not RecruitingUnknown Status

Show 7 earlier versions
  1. Apr 2021 — Feb 2023 [monthly]

    Active Not Recruiting NA

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting NA

  3. Sep 2019 — Jan 2021 [monthly]

    Active Not Recruiting NA

    Status: Unknown StatusActive Not Recruiting · Phase: PHASE2NA

  4. Feb 2019 — Sep 2019 [monthly]

    Unknown Status PHASE2

    Status: Active Not RecruitingUnknown Status

  5. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Accuray Incorporated
Data source: Accuray Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .